Citations (15)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Marte Karen Brattås, Håkon Reikvam, Tor Henrik Anderson Tvedt & Øystein Bruserud. (2019) Dasatinib as an investigational drug for the treatment of Philadelphia
chromosome-positive acute lymphoblastic leukemia in adults. Expert Opinion on Investigational Drugs 28:5, pages 411-420.
Read now
Read now
Articles from other publishers (14)
Katie Voelz, Anthony Salvatore, Sudarshawn Damodharan & Cathy Lee‐Miller. (2023) Need for pneumococcal revaccination after blinatumomab therapy: A case report. Pediatric Blood & Cancer 70:6.
Crossref
Crossref
Violeta Graiqevci-Uka, Emir Behluli, Lidvana Spahiu, Thomas Liehr & Gazmend Temaj. (2023) Targeted Treatment and Immunotherapy in High-risk and Relapsed/
Refractory Pediatric Acute Lymphoblastic Leukemia. Current Pediatric Reviews 19:2, pages 150-156.
Crossref
Crossref
Ashley Pinchinat, Sumit Gupta, Stacy L. Cooper & Rachel E. Rau. (2023) SOHO State of the Art Updates and Next Questions | Optimal Timing of Blinatumomab for the Treatment of B-Acute Lymphoblastic Leukemia. Clinical Lymphoma Myeloma and Leukemia 23:3, pages 159-167.
Crossref
Crossref
Shuning Wei, Runxia Gu, Yang Song, Zhangsong Yan, Yimin Hu, Dong Lin, Kaiqi Liu, Chunlin Zhou, Guangji Zhang, Ying Wang, Jianxiang Wang & Yingchang Mi. (2022)
Early‐salvage
therapy with venetoclax‐based regimens for induction failure and poor early response acute lymphoblastic leukaemia: A retrospective case series of 13 patients
. British Journal of Haematology 199:5, pages 772-776.
Crossref
Crossref
Khushi Rathod, Shravani Rani & Shreerachita Satish. (2021) Efficacy of CRISPR-Cas9 CAR T-Cell Therapy vs. Blinatumomab in the Treatment of Acute Lymphoblastic Leukemia. Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal 5:5, pages 1-7.
Crossref
Crossref
Ho Jung Choi, Jung Yoon Choi, Bo Kyung Kim, Hong Yul An, Kyung Taek Hong, Hee Young Shin & Hyoung Jin Kang. (2021) Combination Therapy With Chemotherapy, Donor Lymphocyte Infusion With Concurrent Blinatumomab in Relapsed/Refractory Acute Precursor B-Lymphoblastic Leukemia. Journal of Pediatric Hematology/Oncology 43:2, pages e280-e283.
Crossref
Crossref
Manisha Agarwal, Rachna Seth & Tathagata Chatterjee. (2020) Recent Advances in Molecular Diagnosis and Prognosis of Childhood B Cell Lineage Acute Lymphoblastic Leukemia (B-ALL). Indian Journal of Hematology and Blood Transfusion 37:1, pages 10-20.
Crossref
Crossref
Aaron D. Goldberg, Ehab Atallah, David Rizzieri, Roland B. Walter, Ki-Young Chung, Alexander Spira, Wendy Stock, Martin S. Tallman, Hans G. Cruz, Joseph Boni, Karin E.G. Havenith, Grace Chao, Jay M. Feingold, Jens Wuerthner & Melhem Solh. (2020) Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study. Leukemia Research 95, pages 106385.
Crossref
Crossref
Alexander Gavralidis & Andrew M. Brunner. (2020) Novel Therapies in the Treatment of Adult Acute Lymphoblastic Leukemia. Current Hematologic Malignancy Reports 15:4, pages 294-304.
Crossref
Crossref
Kathryn A. Culos, Katie S. Gatwood & Michael Byrne. (2020) Maintenance Strategies After Hematopoietic Cell Transplantation. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 40:8, pages 727-740.
Crossref
Crossref
Franco Locatelli, Gerhard Zugmaier, Noemi Mergen, Peter Bader, Sima Jeha, Paul-Gerhardt Schlegel, Jean-Pierre Bourquin, Rupert Handgretinger, Benoit Brethon, Claudia Rossig & Christiane Chen-Santel. (2020) Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study. Blood Cancer Journal 10:7.
Crossref
Crossref
Alessandro Rambaldi, Francoise Huguet, Pavel Zak, Paul CannellQui Tran, Janet Franklin & Max S. Topp. (2020) Blinatumomab consolidation and maintenance therapy in adults with relapsed/refractory B-precursor acute lymphoblastic leukemia. Blood Advances 4:7, pages 1518-1525.
Crossref
Crossref
Teilo H Schaller, David J Snyder, Ivan Spasojevic, Patrick C Gedeon, Luis Sanchez-Perez & John H Sampson. (2020) First in human dose calculation of a single-chain bispecific antibody targeting glioma using the MABEL approach. Journal for ImmunoTherapy of Cancer 8:1, pages e000213.
Crossref
Crossref
Ana Bela Sarmento-Ribeiro, Andreas Scorilas, Ana Cristina Gonçalves, Thomas Efferth & Ioannis P. Trougakos. (2019) The emergence of drug resistance to targeted cancer therapies: Clinical evidence. Drug Resistance Updates 47, pages 100646.
Crossref
Crossref